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Reply
We read Dr Garcı´a-Rinaldi’s letter with interest, and are
familiar with his report published in 2002. In his letter, Dr Garcı´a-
Rinaldi points out the fundamental difference in the patient pop-
ulations that received treatment, which makes any comparison of
patency and competency of the two techniques invalid. The mo-
nocusp patch is used in a group of patients with primary insuffi-
ciency without previous thrombotic events. In contrast, we at-
tempt to control reflux in patients with severe thrombotic disease.
Our group of patients is not only “thrombosis prone,” but the
target vessel is severely diseased with thickened wall, often trabec-
ulated lumen, and scarred, uneven endothelium. Retaining the
posterior aspect of the patient’s own vessel wall might be prudent
in nonthrombotic disease with smooth endothelium enabling
good apposition of the monocusp, but it might prove inadequate
in a postthrombotic vessel.
We recognize Dr Garcı´a-Rinaldi’s excellent short-term results
with the cryopreserved monocusp patch in primary disease, and
look forward to evaluation of this technique when used to control
reflux in postthrombotic disease.
Peter Negle´n, MD, PhD
Seshadri Raju, MD
River Oaks Hospital
Jackson, Miss
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Regarding “Is there an increased risk for DVT with
the VNUS closure procedure?”
In a letter to the Editor, Komenaka and Nguyen (J Vasc Surg
2002;36:1311) reported that deep venous thrombosis developed
in 2 of 29 patients after varicose vein ablation with the VNUS
closure device. This 6.8% incidence seems high, compared with the
generally reported 0.8% to 1.3% risk for deep venous thrombosis
with varicose vein treatment.1,2
The US Food and Drug Administration (FDA) approved the
VNUS closure catheter in 1998 as “substantially equivalent to”
seven older devices. Thus safety data based on results of trials in
human beings for this class II approval were not submitted. The
closure device generates interest for improving conventional vari-
cose vein surgery, but, in the absence of controlled trials, reports of
its advantages seem premature.3 The FDA Manufacturer and User
Facility Device Experience Database (MAUDE)4 presently in-
cludes 20 reports of serious adverse events after use of this device.
As a result of gross underreporting, the FDA estimates this to
represent less than 1% of actual serious adverse events occurring in
clinical practice.
Only one report (5%) describes a manufacturing defect,
whereas 19 reports (95%) involve deep vein thrombosis or ascend-
ing thrombosis. Three reports (16%) mention pulmonary embo-
lism, but because of patients lost to follow-up, mortality could not
be assessed. Most patients (n 12; 63%) received anticoagulation
therapy, with or without thrombectomy or saphenofemoral junc-
tion ligation. Faulty technique was reported in only two patients
(10%); it is surprising that the procedure was declared successful,
“irrespective of the thrombosis,” in nine patients (47%).
These reports in the MAUDE database raise substantial con-
cern about the incidence of deep vein thrombosis after VNUS
closure or radiofrequency ablation of varicose veins, which must be
carefully addressed by the FDA and the manufacturer.
R. C. Guptan, MD
Venous Research Foundation
Schaumburg, Ill
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Regarding “Carotid artery stenting: Analysis of data
for 105 patients at high risk”
I read with interest the article by Hobson et al (J Vasc Surg
2003;37:1234-9) regarding carotid artery stenting (CAS). I be-
lieve the article makes a further, important contribution to evalu-
ating this procedure.
The article suggests some concerns about CAS. The technique
involves some issues that must be debated, including indications,
cerebral protection, and immediate and long-term results.
I would like to focus on indications for the technique. Hobson
and colleagues suggest that CAS can be used in patients at poor or
high surgical risk, including those with concomitant morbid con-
ditions, recurrent stenosis, stenosis after cervical irradiation, and
anatomic features of carotid stenosis.
From this point of view, CAS is an alternative to carotid
endarterectomy (CEA), and the two should be compared. In
comparing these procedures, we must take into account the cur-
rent results of CEA. I agree with Hobson and colleagues regarding
preference for CAS in patients with post-irradiation stenosis and
recurrent stenosis. As stressed by the authors, CEA results for
recurrent stenosis were not as good as for primary stenosis. To
indications for CAS, I would add carotid stenosis with some
anatomic characteristics, for example, stenosis involving the distal
extracranial internal carotid artery. When considering CAS in the
subgroup of patients with comorbid conditions, I believe some
caution is needed. In the report by Hobson and colleagues, CAS
was followed by complications in 2.85% of patients. After nonin-
vasive diagnostic testing, including duplex scanning and, in some
cases, multisection computed tomography angiography or mag-
netic resonance imaging angiography, CEA can be performed with
the patient under local anesthesia. This avoids complications
caused by arteriography, which is necessary for CAS and was
responsible for complications in 4.7% of patients. Local anesthesia
has significant advantages over general anesthesia, such as capabil-
ity for neurologic monitoring, lower incidence of stroke,1 stable
cardiovascular condition,2 and better cerebral perfusion during
carotid artery occlusion.3
These observations are supported by experience at our insti-
tution.4 The cumulative incidence of perioperative stroke and
mortality was 0.7% in a series of 147 patients with symptomatic or
asymptomatic stenosis who were operated on under local anesthe-
sia. This series included numerous patients with comorbid condi-
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